128 related articles for article (PubMed ID: 3690804)
1. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.
Speth PA; Linssen PC; Boezeman JB; Wessels HM; Haanen C
Cancer Chemother Pharmacol; 1987; 20(4):311-5. PubMed ID: 3690804
[TBL] [Abstract][Full Text] [Related]
2. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin.
Speth PA; van de Loo FA; Linssen PC; Wessels HM; Haanen C
Clin Pharmacol Ther; 1986 Dec; 40(6):643-9. PubMed ID: 3465490
[TBL] [Abstract][Full Text] [Related]
3. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.
Speth PA; Linssen PC; Boezeman JB; Wessels HM; Haanen C
Cancer Chemother Pharmacol; 1987; 20(4):305-10. PubMed ID: 3480081
[TBL] [Abstract][Full Text] [Related]
4. Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia.
Lewis JP; Meyers FJ; Tanaka L
Br J Haematol; 1985 Oct; 61(2):261-5. PubMed ID: 4041369
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.
Muller C; Chatelut E; Gualano V; De Forni M; Huguet F; Attal M; Canal P; Laurent G
Cancer Chemother Pharmacol; 1993; 32(5):379-84. PubMed ID: 8339389
[TBL] [Abstract][Full Text] [Related]
6. Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.
Nooter K; Sonneveld P; Martens A
Cancer Res; 1985 Sep; 45(9):4020-5. PubMed ID: 4027999
[TBL] [Abstract][Full Text] [Related]
7. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.
Duncan R; Kopecková P; Strohalm J; Hume IC; Lloyd JB; Kopecek J
Br J Cancer; 1988 Feb; 57(2):147-56. PubMed ID: 3358905
[TBL] [Abstract][Full Text] [Related]
8. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.
Paul C; Tidefelt U; Liliemark J; Peterson C
Leuk Res; 1989; 13(2):191-6. PubMed ID: 2927175
[TBL] [Abstract][Full Text] [Related]
9. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
10. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia.
DeGregorio MW; Carrera CJ; Klock JC; Pegelow CH; Wilbur JR
Cancer Treat Rep; 1982 Dec; 66(12):2085-8. PubMed ID: 6958366
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion.
Speth PA; Linssen PC; Holdrinet RS; Haanen C
Clin Pharmacol Ther; 1987 Jun; 41(6):661-5. PubMed ID: 3581649
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution and myelotoxicity of daunomycin in the rat: rapid bolus injection vs continuous infusion.
Nooter K; Sonneveld P; Martens A; Hagenbeek A; Schultz F
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):801-6. PubMed ID: 3770038
[TBL] [Abstract][Full Text] [Related]
13. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
14. Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.
Andersson B; Beran M
Cancer Chemother Pharmacol; 1980; 4(3):205-7. PubMed ID: 7397945
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of daunomycin in leukemia cells and leukocytes in vivo in the rat.
Sonneveld P; Kokenberg E; van der Steuijt K; Nooter K
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1109-16. PubMed ID: 3477464
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and therapeutic efficacy of daunomycin:DNA complex in mice.
Ohnuma T; Holland JF; Chen JH
Cancer Res; 1975 Jul; 35(7):1767-72. PubMed ID: 1131831
[TBL] [Abstract][Full Text] [Related]
17. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
Kokenberg E; Sonneveld P; Sizoo W; Hagenbeek A; Löwenberg B
J Clin Oncol; 1988 May; 6(5):802-12. PubMed ID: 3163363
[TBL] [Abstract][Full Text] [Related]
18. Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.
Tseng E; Kamath A; Morris ME
Pharm Res; 2002 Oct; 19(10):1509-15. PubMed ID: 12425469
[TBL] [Abstract][Full Text] [Related]
19. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Steinherz PG; Redner A; Steinherz L; Meyers P; Tan C; Heller G
Cancer; 1993 Nov; 72(10):3120-30. PubMed ID: 8221579
[TBL] [Abstract][Full Text] [Related]
20. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
